ABSTRACT
Objective To explore promoter methylation of HIC1 gene and the expression of HIC1/SIRT1 related to the occurrence, development, and metastasis of papillary thyroid carcinoma. Methods Using Bisulfite sequencing PCR to analyze the promoter methylation of HIC1 gene. Using quantitative real-time PCR and Western blot to analyze expression differences of HIC1 and SIRT1 genes in tissues of papillary thyroid carcinoma(40 cases) and in adjacent normal thyroid(40 cases), of which datas were analyzed by statistics. Results The degree of HIC1 gene promoter methylation was significantly higher than that in adjacent normal tissues(P<0. 01). The degree of HIC1 gene promoter methylation in papillary thyroid carcinoma was related to lymph node metastasis, age, and the tumor-node-metastasis stages(P<0. 01). Compared with the expression of HIC1 mRNA and protein in adjacent normal thyroid tissue, that in papillary thyroid carcinoma was significantly lower(P<0. 01), while the expression of SIRT1 mRNA and protein in papillary thyroid carcinoma was significantly higher(P<0. 01). The lower expression of HIC1 mRNA and protein in the tumor tissues was related to the stage of lymph node metastasis, age, and the tumor-node-metastasis stages(P<0. 05). There was a strong negative correlation between the degree of HIC1 gene promoter methylation and expression of HIC1 in papillary thyroid carcinoma(P<0. 05). The expression of HIC1 mRNA and protein between that of SIRT1 also showed a strong negative correlation(P<0. 01). Conclusion Promoter hypermethylation of HIC1 and aberrant expression of HIC1/SIRT1 in papillary thyroid carcinoma may play a significant role in the oncogenesis and progress of papillary thyroid carcinoma. HIC1 is expected to become a new marker for prevention and treatment of papillary thyroid carcinoma.
ABSTRACT
Objective To study the expression of activated leukocyte cell adhesion molecule (ALCAM/CD166) in serous ovarian tumors and its significance.Methods The expression level of CD166 protein,estrogen receptor,progestogen receptor were detected by immunohistochemical staining in 56 cases of malignant tumors,30 cases of borderline tumors and 10 cases of benign tumors,the relationship was investigated between the expression of CD166 and clinicopathologic information and its correlation with the expression of estrogen receptor (ER) and progestogen receptor (PR).Results The positive rates of CD166 protein in malignant,borderline and benign epithelial ovarian tumors were 87.5 ％ (49/56),56.7 ％ (17/30) and 10.0 ％ (1/10) respectively,there were significant differences (x2 =7.463,31.054,10.563,all P ＜ 0.01).There were also significant differences in positive rates of CD166 protein among different clinical stages,pathologic grades and lymph node metastasis of epithelial ovarian tumors (x2 =41.205,Z =-4.663,Z =-2.981,all P ＜ 0.01).There was a negative correlation between the expression of CD166 protein and the leves of ER and PR (x2 =23.36,21.441,both P ＜ 0.05).Conclusion CD166 takes part in development and progression of serous ovarian carcinoma.The expression of CD166 increase significantly in ovarian serous carcinoma.